1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

Size: px
Start display at page:

Download "1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1"

Transcription

1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY 1 Cutting Edge Science 0950 imig Special Keynote Lecture Stem cells 1030 COFFEE CONCURRENT 1A, 1B, 1C Mesothelioma Epidemiology Biomarkers Surgery Symposium 1300 LUNCH 1400 PLENARY 2 - imig medallists session - What have we learnt over the past 50 years? 1530 TEA & POSTERS 1600 CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 Sundowner sessions Genomics Clinical FREE EVENING & IMIG BOARD DINNER 23 Oct Thursday 0830 PLENARY 3 The best of imig COFFEE 1300 LUNCH CONCURRENT 2A, 2B, 2C Combination therapy Nursing Immunology 2 - Clinical trials CONCURRENT 2D, 2E, 2F 1400 Trials in progress: investigators Optimising surgery Optimising Radiotherapy are invited to submit theirs 1530 TEA & POSTERS CONCURRENT 2G, 2H, 2J 1600 Genomics Novel therapeutics: Clinical Pathology Trials Sundowner sessions Biology and biomarkers Chemotherapy have we gone as far as we can go? 1830 on GALA DINNER AND DRUMMING 24 Oct Friday 0830 CONCURRENT 3A, 3B, 3C Social Advocacy Early drug development Personalised therapy 1000 COFFEE 10:30 CONCURRENT 3D, 3E, 3F Animal /Preclinical models Peritoneal mesothelioma Imaging for Mesothelioma 1200 PLENARY 4 CLOSING SESSION All venues are at the Cape Town International Conference Centre CTICC unless otherwise specified

2 DAY 1 WEDNESDAY October REGISTRATION AT CTICC OPENING and WELCOME Presidential Address Opening address by the. Minister of Health South Africa PLENARY 1 Genomics: Tumour Genome Atlas-mesothelioma. An update Mesothelioma--From Chaos to Mitochondrial Functionality. Novel strategies for therapeutic inhibition or What the fractal? 0950 IMIG SPECIAL KEYNOTE LECTURE - Cancer stem cells as a target pathways A 1B 1C COFFEE Epidemiology for Mesothelioma Keynote Presentation Current western mesothelioma epidemics Predicting mesothelioma incidence near Kuruman, South Africa - the MINKS study The South African legacy of asbestos - then and now Mapping environmental asbestos pollution in South Africa Ceramic fiber exposure and Mesothelioma Occasional exposure to asbestos: what is the risk Biomarkers Challenges in development of biomarkers Molecular prognostic factors in practice Pitfalls in biomarker research Surgery Symposium IMIG/IASLC staging The state of the art technique for extrapleural pneumonectomy The state of the art technique for lung-sparing surgery Save the lung or take the lung?-advantages and disadvantages of extrapleural pneumonectomy and pleurectomy decortication Personalising surgery 2

3 LUNCH PLENARY 2 imig medallists - What have we learnt over the past 50 years? Cell lines and animal models Biomarkers and immunotherapy Surgery and other conventional therapies Gene therapy and other novel therapies Understanding signalling events Understanding molecular lesions and events TEA & POSTERS POSTERS - Author stand by posters for discussion with delegates SURGERY: NOVEL THERAPEUTICS: IMAGING AND STAGING: PATHOLOGY AND CYTOLOGY: PROGRAMMATIC APPROACH AND EDUCATIONAL RESOURCES FOR MESOTHELIOMA CARE: D Biology and Pathogenesis Keynote presentation: The BAP1 Cancer Syndrome Suggest PI3K/mTOR Hippo pathway mutations in mesothelioma 1E 1F Multi-Modality Combining chemotherapy and/or radiation with surgery, before, after, never or both: what is the rationale, what is the evidence? Intraoperative adjuvant therapies for malignant pleural mesothelioma -worthwhile or waste of time? Patient selection for multimodality therapy-what is the evidence Immunology 1 Keynote: Let s think outside the box-can we combine surgery and immunotherapy? Should we? How would we? 3

4 Immune microenvironment of mesothelioma Phase I trial of Mesothelin-CAR redirected autologous T cells in human- Checkpoint blockade Dendritic cell treatment results of current studies- What is the place of anti-pd1 treatment in MPM- Discussion SUNDOWNERS 1G 1H Genomics best approaches to understanding molecular lesions. Strengths and pitfalls. How it might inform us about diagnosis, pathogenesis, new pathological categorization and new therapies Clinical topic - FREE EVENING & IMIG BOARD DINNER DAY 2 THURSDAY, October 23 PLENARY 3 - The best of imig the top submitted abstracts (the best abstracts) A 2B COFFEE Combination therapy for Mesothelioma Neo-adjuvant therapy and surgery Changes in FAK and cancer stem cell expression after chemotherapy Novel radiation schedules after surgery Adjuvant therapies after first line treatment Discussion (round table) Nursing Promoting entry into clinical trials & improving access to specialist treatment and care Improving outcomes in Mesothelioma-An international approach to meeting nurses educational needs 4

5 2C Developing and coordinating a specialist mesothelioma program of treatment and care Palliative care in Kuruman-setting up a community oasis Immunology 2 - Clinical trials Keynote Presentation Anti-mesothelin immunotoxin in mesothelioma Phase 2 trial of intrapleural Ad.IFN Anti-CTLA4 checkpoint blockade in patients with mesothelioma Anti CD D LUNCH Trials in progress Investigators are invited to submit their current trials in progress for presentation 2E 2F Optimising surgery P/D the best there is? How to implement surgery in a combined modality approach MARS2 After surgical treatment: A critical appraisal Surgery for MPM - how should we select patients today and how will we select them in five years Optimising Radiotherapy Radioresponsiveness, Rationale, and Roles for Radiation Therapy for Mesothelioma Radiotherapy Techniques and Outcomes After Radical Pleurectomy for Mesothelioma Neoadjuvant Radiation Therapy in Mesothelioma Patients Receiving Extrapleural Pneumonectomy Future Horizons for Radiation Therapy for Mesothelioma: Radiobiology and Immunotherapy TEA & POSTERS POSTERS - Author stand by posters for discussion with delegates DIAGNOSTIC AND PREDICTIVE BIOMARKERS: TRIALS IN PROGRESS POSTER SESSION MULTIMODALITY: 5

6 IMMUNOLOGY: RADIATION THERAPY AND BIOLOGY: G Genomics Keynote presentation:. Tumour suppressors in MPM Genetic targets Genomics and drug sensitivity-r SWAMP study- (UK) 2H Novel therapeutics: Clinical Trials Keynote presentation Novel therapeutics Triple angiokinase inhibition PD-1 Integrating immune checkpoint modulation into therapy for MM FAK 2J Pathology Keynote presentation: Using cytology for MPM diagnosis Cytogenetics for diagnosis Mesobank UK Mesoscape Pathological challenges in diagnosing mesothelioma Clinico-autopsy accuracy in diagnosing asbestos disease SUNDOWNERS 2K 2L Biology and biomarkers How does the biology of MM, especially tumor cell signaling, immunology and tumor microenvironment, inform us about screening, diagnosis, new therapies and disease monitoring Chemotherapy - have we gone about as far as we can go? What is the best way to approach this in the lab and clinic moving forward eg. Mechanisms of chemotherapy resistance? Combined therapies, personalized therapies etc? 1830 on GALA DINNER AND DRUMMING 6

7 A DAY 3 FRIDAY, October 24 Social Advocacy The Global Asbestos Landscape 2014 The critical role scientists and health professionals can play to prevent asbestos-related harm. Recent examples and lessons learned. Limitations of legal recourse in South Africa for mesothelioma victims 3B 3C D Asbestos blues a history of asbestos mining in South Africa Models for early drug development Keynote Presentation- Spheroids and drug sensitivity Primary MPM cultures and multiple drug testing PROOF study: which patient to treat with outcome of primary culture testing) Preclinical molecular pathogenesis of preclinical asbestos induced mesothelioma Towards Personalised therapy Keynote Presentation Human and mouse sequencing data NF2 and FAK-synthetic lethality Targeting NF2 CDKN2A CDKNA and synthetic lethality COFFEE Animal/Preclinical models Keynote Presentation: Spontaneous tumor models in MPM 3E Peritoneal Mesothelioma Keynote Presentation 3F Imaging for Mesothelioma 7

8 1200 PLENARY 4 and CLOSING Closing Session Presentation of Young Investigator & Travel Awards Keynote presentation Closing Remarks and Welcome to imig

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

An update in Mesothelioma and Thymoma Management

An update in Mesothelioma and Thymoma Management An update in Mesothelioma and Thymoma Management ASCO 2014 update Khalid Alsaleh King Saud University FRCPC, FACP, MSc Mesothelioma Outline Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma

More information

Griffith University - Case for Support. Mesothelioma Research Program

Griffith University - Case for Support. Mesothelioma Research Program Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health

More information

Tuesday, February 28, 2017 Auditorium I Meeting Room 2.40 Meeting Room 2.60 Meeting Room 1.40 Joint Public

Tuesday, February 28, 2017 Auditorium I Meeting Room 2.40 Meeting Room 2.60 Meeting Room 1.40 Joint Public Public Health Clinical Clinical Track Basic Science Plenary Poster Public Health Track Basic Science Track Networking Event General Assembly Tuesday, February 28, 2017 Auditorium I Meeting Room 2.40 Meeting

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

EUROPEAN ASSOCIATION FOR CANCER RESEARCH STATISTICS REPORT 23 rd Biennial Congress of the EUROPEAN ASSOCIATION FOR CANCER RESEARCH From Basic Research to Personalised Cancer Treatment German Cancer Society Experimental Cancer Research Registration

More information

International Symposium on Malignant Pleural Mesothelioma

International Symposium on Malignant Pleural Mesothelioma International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear

More information

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D.

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D. FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

Mesothelioma in the UK

Mesothelioma in the UK Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant 2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February

More information

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis Tuesday, Aug. 31 Room A Time: 8:00-8:10 Opening Remarks Time: 8:10-8:35 The mesothelial cell ES01 Time: 8:35-9:00 Educational Session Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School,

More information

Bristol-Myers Squibb Independent Medical Education

Bristol-Myers Squibb Independent Medical Education Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date 3/1/2017 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD Title: IME Specialist, Oncology

More information

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M.

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. Patronage requested Faculty A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. FIGINI (MILAN) J. GALON (PARIS) G. KROEMER (PARIS) M. MAIO (SIENA)

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

Thank you to our webinar sponsors:

Thank you to our webinar sponsors: Treatment Approaches for Pancreatic Cancer January 27, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

Please see the LUCADA data manual v3.1.3, available in the downloads section

Please see the LUCADA data manual v3.1.3, available in the downloads section National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

The Brain and Spine CenTer

The Brain and Spine CenTer The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas

More information

PROGRAMMA SCIENTIFICO

PROGRAMMA SCIENTIFICO PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

May 18, 2013 Sheraton Delfina Santa Monica, California

May 18, 2013 Sheraton Delfina Santa Monica, California 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma May 18, 2013 Sheraton Delfina Santa Monica, California Malignant pleural mesothelioma (MPM) is an unusual cancer

More information

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology Radiation Oncology Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology This exam tests your knowledge of the principles of cancer and radiation biology

More information

May 18, 2013 Sheraton Delfina Santa Monica, California

May 18, 2013 Sheraton Delfina Santa Monica, California 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma May 18, 2013 Sheraton Delfina Santa Monica, California Malignant pleural mesothelioma (MPM) is an unusual cancer

More information

Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting

Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting 1 Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting Siena - October 17-19, 2013 Scientific Committee: NIBIT Board of Directors Thursday, October 17 12:00 Arrival/Registration/Light lunch 14:00 Welcome

More information

Friday 29 th, October 2010

Friday 29 th, October 2010 Friday 29 th, October 2010 15:00-17:00 Registration 17:00-18:00 Opening Ceremony 18:00-18:30 Refreshment Break 18:30-19:00 Plenary Lecture I Nazli Gad El Mawla Memorial Lecture Chairpersons: Prof. Dr.

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

Mesothelioma Applied Research Foundation www.curemeso.org

Mesothelioma Applied Research Foundation www.curemeso.org Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Eastern North Carolina Lung Cancer Symposium

Eastern North Carolina Lung Cancer Symposium Eastern North Carolina Lung Cancer Symposium Friday, October 30, 2015 The East Carolina Heart Institute 115 Heart Drive Greenville, North Carolina Jointly Provided by The Department of Internal Medicine

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

Asbestos-Related Cancer Research and Prevention

Asbestos-Related Cancer Research and Prevention Asbestos-Related Cancer Research and Prevention Professor Nico van Zandwijk Asbestos Diseases Research Institute University of Sydney International Conference on Asbestos Awareness and Management 18 November

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Lung Cancer in 2015: A Multidisciplinary Update

Lung Cancer in 2015: A Multidisciplinary Update Lung Cancer in 2015: A Multidisciplinary Update Invited Guest Faculty: Toronto General Hospital Toronto, Canada Saturday April 18, 2015 7:00 am-4:30 pm Westin Pasadena 191 N. Los Robles Avenue Pasadena,

More information

M E S O T H E L I O M A Questions & Answers

M E S O T H E L I O M A Questions & Answers M E S O T H E L I O M A Questions & Answers A G U I D E F O R M E S O T H E L I O M A P A T I E N T S A N D T H E I R L O V E D O N E S MORGAN & MORGAN FORTHEPEOPLE.COM 877-667-4265 Mesothelioma Questions

More information

THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA

THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1

More information

Australian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Oncology Paper 1

Australian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Oncology Paper 1 Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2016 Veterinary Oncology Paper 1 Perusal time: Twenty (20) minutes Time allowed: Four (4) hours after perusal Answer

More information

Master Online Study Program @dvanced Oncology. Study part time team up internationally!

Master Online Study Program @dvanced Oncology. Study part time team up internationally! Master Online Study Program @dvanced Oncology Study part time team up internationally! Ulm University is developing an innovative international postgraduate study program @dvanced Oncology addressing clinical

More information

So these combination of treatments became a standard for inflammatory breast cancer treatment.

So these combination of treatments became a standard for inflammatory breast cancer treatment. Hi. I am Naoto Ueno. I am a medical oncologist at The University of Texas MD Anderson Cancer Center. I also represent Executive Director of The Morgan Welch IBC Research Program and Clinic. Today I would

More information

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION

More information

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain CNIO Frontiers Meetings Primary and Secondary Brain Tumors 19th 22nd February 2017 Organisers: Richard Gilbertson CRUK Cambridge Institute, UK Michael Weller University Hospital Zurich, Switzerland Massimo

More information

Level 1. Nutrition & Lifestyle Oncology Certificate

Level 1. Nutrition & Lifestyle Oncology Certificate Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

Molecular Testing in Breast Cancer: An Oncologist s Perspective

Molecular Testing in Breast Cancer: An Oncologist s Perspective Molecular Testing in Breast Cancer: An Oncologist s Perspective Adam L. Cohen, MD, MS Assistant Professor Huntsman Cancer Institute, University of Utah Adam.cohen@hci.utah.edu Park City AP Pathology Update

More information

Understanding Pleural Mesothelioma

Understanding Pleural Mesothelioma Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to

More information

Update on Clinical Trials and Foundation Funded Grants

Update on Clinical Trials and Foundation Funded Grants Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control

More information

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Saturday, April 27, 2013 Cleveland Marriott Downtown at Key Center 127 Public Square Cleveland, Ohio Learning

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

Institute Agenda San Diego, CA

Institute Agenda San Diego, CA Meeting Room Locations: Meals: General Session Lectures: Study Group A: Study Group B: Study Group C: Study Group D: Study Group E: Study Group F: Institute Agenda San Diego, CA Sunday 2:00pm 3:00pm 3:00pm-3:05pm

More information

UC Brain Tumor Center Molecular Therapeutics Pilot Grant Program 2016/2017

UC Brain Tumor Center Molecular Therapeutics Pilot Grant Program 2016/2017 UC Brain Tumor Center Molecular Therapeutics Program Request for Applications The UC Brain Tumor Center (BTC) invites applications to support new and continuing research projects working to improve the

More information

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA 17-18 June 2010 Golnik, Slovenia Chair: T. Cufer, SI - G.L. Ceresoli, IT AIM OF THE COURSE The incidence

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) 2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region April 2016 27-30 Santiago - Chile Hotel Diego de Almagro San Pío X 2530, Providencia, Santiago. INFORMATION www.lungcancerworkshop.cl

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Fukushima Global Medical Science Center

Fukushima Global Medical Science Center Fukushima Medical University Fukushima Global Medical Science Basic Concept Image 2012Digital Earth Technology 2012Cnes/Spot Image DataSIO.NOAA.U.S.Navy.NGA.GEBCO Image 2012GeoEye Google earth Introduction

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto

New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic

More information

Melanoma information card

Melanoma information card Melanoma statistics Malignant melanoma is estimated to represent 4% of all skin cancers and is responsible for 80% of deaths from skin cancer. (Cancer Research UK, Miller and Mihm, 2006) Cases of skin

More information

PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/ Mayo Foundation for Medical Education and Research. All rights reserved.

PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/ Mayo Foundation for Medical Education and Research. All rights reserved. PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/2017 1 2 I have nothing to disclose. 3 MPGN Part 1 2/6/2017 As you view this presentation, consider the following important points regarding testing. How

More information

How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society

How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society Objectives Name two possibilities for using information obtained through molecular profiling

More information

INSTITUTE OF MEDICINE WORKSHOP. Workshop Overview

INSTITUTE OF MEDICINE WORKSHOP. Workshop Overview INSTITUTE OF MEDICINE WORKSHOP June 8-9, 2015 The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research Workshop Overview Kastan, MD, PhD Michael B. Duke Cancer

More information

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis

Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis Tuesday, Aug. 31 Room A Time: 8:00-8:10 Opening Remarks Time: 8:10-8:35 The mesothelial cell ES01 Time: 8:35-9:00 Educational Session Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School,

More information

First International Gliomatosis cerebri (GC) group meeting. March 26 27, Paris, France

First International Gliomatosis cerebri (GC) group meeting. March 26 27, Paris, France First International Gliomatosis cerebri (GC) group meeting. March 26 27, 2015. Paris, France Thursday March 26 10:30 am 11:00 am Registration 11:00 am 11:15 am Welcoming: Andres Morales Foundations and

More information

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International

More information

BSc Biomedical Sciences

BSc Biomedical Sciences SCHOOL OF HEALTH SCIENCES AND SOCIAL CARE BIOSCIENCES Undergraduate Courses with pathways in: (Biochemistry) (Forensic) (Genetics) (Human Health) (Immunology) All courses available in 3 years full-time

More information

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1 Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information

Breast cancer research and a changing treatment pathway

Breast cancer research and a changing treatment pathway Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery

More information

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

Dogs, Genes, and Cancer: Why Cancer Happens and What We Can Do to Prevent and Treat It.

Dogs, Genes, and Cancer: Why Cancer Happens and What We Can Do to Prevent and Treat It. Dogs, Genes, and Cancer: Why Cancer Happens and What We Can Do to Prevent and Treat It. Introduction. Due to advances in veterinary health care, dogs are living to older age when most cancer types occur

More information

About Renal Cell Carcinoma

About Renal Cell Carcinoma Renal Cell Carcinoma Incidence and Prevalence Kidney Cancer Prevalence Worldwide ESTIMATED 2012 CASES Less than 50,000 ASIA 123,402 AFRICA 10,033 SOUTH AMERICA 15,661 Renal cell carcinoma, or RCC, is the

More information

From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes

From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes ISSN 2154-4006 The Genetic Basis of Human Disease zbar Colloquium series on Series Editor: Michael Dean, Ph.D., Head, Human Genetics Section, Senior Investigator, Laboratory of Experimental Immunology

More information

May 21, 2011 Sheraton Delfina Santa Monica, California

May 21, 2011 Sheraton Delfina Santa Monica, California 1st International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma May 21, 2011 Sheraton Delfina Santa Monica, California Malignant pleural mesothelioma (MPM) is an unusual cancer

More information

Wednesday 4 th May 2016

Wednesday 4 th May 2016 Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease Wellcome Genome Campus Hinxton, Cambridge, UK 4-6 May 2016 Draft Conference Programme Wednesday 4 th May 2016 11:30-12:50 Registration

More information